Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Pharmaessentia Corp.

Headquarters: Taipei, Taiwan
Year Founded: 2003
Status: Public
Industry Sector: HealthTechnology
CEO: Kuo Chung Lin, PhD
Number Of Employees: 459
Enterprise Value: $4,104,490,756
PE Ratio: -110.79
Exchange/Ticker 1: TPEx:6446
Exchange/Ticker 2: N/A
Latest Market Cap: $3,389,916,169

BioCentury | Dec 7, 2024
Management Tracks

Horvat to lead commercial at PharmaEssentia

Plus: New scientific leadership at WEHI and an update from the HIV+Hepatitis Policy Institute
BioCentury | Jul 23, 2024
Management Tracks

Armstrong takes new role at Dana-Farber

Plus: The Carlyle Group’s Rubenstein to join Moderna’s board and updates from Geron, Vedanta, Vericel, Metrion and PharmaEssentia
BioCentury | Jun 21, 2024
Management Tracks

ITM names Cavey CEO, plus PureTech, Brainstorm and more

Plus: New chairs for PureTech, Evexta and updates from PharmaEssentia, Brainstorm, Danaher and more
BioCentury | Apr 24, 2024
Management Tracks

Evotec names Christian Wojczewski CEO

Plus: Novartis proposes Giovanni Caforio as chair and updates from Congruence, Recludix, Calluna and more
BioCentury | Jan 26, 2024
Management Tracks

Karuna vet Paul among new Third Rock venture partners

Plus: three new executives at Soleno and updates from Zentalis, Slingshot, Actio, Kronos, Osivax, Cellular Origins and ConcertAI
BioCentury | Aug 4, 2022
Management Tracks

Sanofi’s Lih-Ling Lin joins PharmaEssentia as CSO

Plus Hunder becomes CMO at ProfoundBio, and updates from Nurix, Sanofi and Nucleai
BioCentury | May 17, 2022
Management Tracks

CRISPR, Nkarta join flurry of CMO moves

Siegall leaving Seagen amid concerns over conduct; new CFO at Mirati and more
BioCentury | Jan 15, 2022
Finance

4Q21 Wrap: the bleeding continues

Biopharmas continued to slump in 4Q21 across all market cap tiers
BioCentury | Nov 16, 2021
Product Development

Nov. 15 Quick Takes: $500M first close of CBC’s biotech facilities venture

Plus PhaseBio, Rhythm, PharmaEssentia and more
BioCentury | Sep 28, 2021
Management Tracks

New hires at Brii, Ono and PharmaEssentia to strengthen U.S. leadership

Plus: Ocular, Genprex, SAB and more
Items per page:
1 - 10 of 23
Username